Ionis Pharmaceuticals Raises Tryngolza Revenue Outlook, Targets 2028 Breakeven

Key Facts

1Ionis raised Tryngolza's peak revenue estimate to over $2 billion following strong clinical data.

2The company projects total peak annual product revenue exceeding $4 billion, plus $2 billion in royalties.

3Management aims to reach cash-flow breakeven by 2028.

Ionis Pharmaceuticals (IONS) has significantly upgraded its long-term financial guidance following strong clinical performance across its drug pipeline. The company raised its peak annual revenue estimate for Tryngolza to over $2 billion, driven by positive data in treating severe hypertriglyceridemia. Management now projects total peak annual product revenue to exceed $4 billion, supplemented by an additional $2 billion in royalty streams. Furthermore, Ionis has established a clear strategic roadmap to reach cash-flow breakeven by 2028. These updates highlight the company's robust fundamental outlook and its successful transition toward commercial-stage growth in the biotechnology sector.